The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV

被引：3

作者：

Snider, Julia Thornton ^{[1
]}

Goldman, Dana P. ^{[2
]}

Rosenblatt, Lisa ^{[3
]}

Seekins, Daniel ^{[3
]}

Juday, Timothy ^{[4
]}

Sanchez, Yuri ^{[4
]}

Wu, Yanyu ^{[1
]}

Peneva, Desi ^{[1
]}

Romley, John A. ^{[2
]}

机构：

[1] Precis Hlth Econ, 11100 Santa Monica Blvd,Suite 500, Los Angeles, CA 90025 USA

[2] Univ So Calif, Los Angeles, CA USA

[3] Bristol Myers Squibb, Plainsboro, NJ USA

[4] AbbVie, Chicago, IL USA

来源：

MEDICAL CARE RESEARCH AND REVIEW | 2016年 / 73卷 / 03期

关键词：

HIV and AIDS; access to care; state policy; government policy; low income; ADJUSTED LIFE-YEAR; ANTIRETROVIRAL THERAPY; COST-EFFECTIVENESS; PRIVATE INSURANCE; CARE; INFECTION; HIV/AIDS; MEDICAID; PROGRAM; HEALTH;

D O I：

10.1177/1077558715614479

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

We investigated the effect of changes to state AIDS Drug Assistance Programs (ADAP) policies, which govern access to antiretroviral therapy (ART), on clinical and economic outcomes among low-income people living with HIV/AIDS. Retrospective analyses of ART access were conducted on state ADAP policies, using data from ADAP Monitoring Reports and Kaiser Family Foundation from 2006 to 2010. We found stricter eligibility requirements reduce the number of HIV-positive individuals with ART access through ADAP, and decreased ART use increases mortality by 2.67 quality-adjusted life years (QALYs) per beneficiary. If the ADAP income eligibility cutoff were decreased by 50 percentage points in each state, 4,626 individuals would lose ART access nationwide. Based on a $22,143 cost/QALY, this policy would save $274 million in health care expenditures (2012 dollars), but result in 12,352 QALYs lost, valued at $1.2 billion. Therefore, states should exercise caution in restricting programs that increase ART access for low-income people living with HIV/AIDS.

引用

页码：329 / 348

页数：20

共 50 条

[21] Exploring the Health Care Environment and Associations with Clinical Outcomes of People Living with HIV/AIDS
Hawk, Mary
Coulter, Robert W. S.
Egan, James E.
Friedman, Mackey Reuel
Meanley, Steven
Fisk, Stuart
Watson, Courtney
Kinsky, Suzanne
AIDS PATIENT CARE AND STDS, 2017, 31 (12) : 495 - 503
[22] The AIDS drug assistance programs and coverage of HIV-related medications
Smith, SR
Buchanan, RJ
ANNALS OF PHARMACOTHERAPY, 2001, 35 (02) : 155 - 166
[23] The impact of unstable housing on HIV treatment outcomes in people living with HIV/AIDS in an urban setting of Southern Europe
Knobel, H.
Guelar, A.
Letang, E.
Acin, P.
Fernandez-Sala, X.
Marin, J.
Lerma, E.
Arrieta, I.
Carbonell, T.
Gonzalez, A.
HIV MEDICINE, 2019, 20 : 160 - 160
[24] Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS
Kathy Lee
Pornpun Vivithanaporn
Reed A Siemieniuk
Hartmut B Krentz
Ferdinand Maingat
M John Gill
Christopher Power
BMC Neurology, 10
[25] Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS
Lee, Kathy
Vivithanaporn, Pornpun
Siemieniuk, Reed A.
Krentz, Hartmut B.
Maingat, Ferdinand
Gill, M. John
Power, Christopher
BMC NEUROLOGY, 2010, 10
[26] Effects of recent Virginia AIDS Drug Assistance Program policy changes on diabetes and hyperlipidemia control in people living with HIV
McManus, Kathleen A.
Pinkerton, Relana
Dillingham, Rebecca
SAGE OPEN MEDICINE, 2014, 2
[27] HIV/AIDS dynamics Impact of economic classes with transmission from poor clinical settings
Pedro, S. A.
Tchuenche, J. M.
JOURNAL OF THEORETICAL BIOLOGY, 2010, 267 (04) : 471 - 485
[28] THE IMPACT OF WORKING WITH PEOPLE WITH HIV AIDS - A REVIEW OF THE LITERATURE
BARBOUR, RS
SOCIAL SCIENCE & MEDICINE, 1994, 39 (02) : 221 - 232
[29] THE IMPACT OF STIGMA ON OLDER PEOPLE LIVING WITH HIV/AIDS
Emlet, C. A.
GERONTOLOGIST, 2009, 49 : 461 - 461
[30] The impact of aging on cancer burden in people with HIV/AIDS
Jerry Polesel
Silvia Franceschi
Barbara Suligoi
Antonella Zucchetto
Diego Serraino
Luigino Dal Maso
Infectious Agents and Cancer, 5 (Suppl 1)

← 1 2 3 4 5 →